CONCLUSIONS: These findings elucidate the GFAT2/HSPD1 axis and O-GlcNAcylation as pivotal metabolic mechanisms underlying EP resistance, identifying them as promising therapeutic targets to overcome chemoresistance in NSCLC. Here, GFPT2 is linked to non-small cell lung carcinoma.